Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
about
Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary diseaseIpratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary diseaseLong acting beta2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trialsUpdate in internal medicine.Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 updateLong acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease.Stable chronic obstructive pulmonary disease.Effects of formoterol inhaled dry powder on exercise performance in chronic obstructive pulmonary disease: a single-center, randomized, double-blind, placebo-controlled, crossover study.Novel therapy for COPD.Chronic obstructive pulmonary disease . 7: Management of COPDAdvances in the management of chronic obstructive pulmonary disease.Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPDEarly onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.New therapies for chronic obstructive pulmonary diseasePharmacological treatment of chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease in China: the potential role of indacaterolImmediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease.Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit.Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPDOnce-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD.Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.Eformoterol n-of-1 trials in chronic obstructive pulmonary disease poorly reversible to salbutamol.Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.
P2860
Q24245141-C010A83B-0C92-417F-9397-AB226E121E9CQ24245413-C90DE549-380A-403B-AD0A-FDEF4B321F31Q24792685-DD1FCD23-99A0-44D6-9B3C-C72E70B0573FQ33588350-9BC9BFBE-6CDE-472B-9979-4373DFD4FA79Q33591899-6B5080E9-8905-4EFC-8720-34C4D8DCA25DQ33691291-BE0AC407-BE04-4AEB-B4B4-CF0CB2DE025BQ33716242-6BFAFDD5-EC07-484A-801F-F83D13AB5065Q33738892-2417C2A4-BF91-417A-AFFC-85E2273C60C2Q34074654-AE7362D0-76BF-485F-8738-A57783A6EB6EQ35075588-BAD2F5CD-A2C7-412F-8649-144EF0E1672AQ35164693-50965191-F027-4E07-A518-F903018F6A99Q35492192-4FC36E83-B7F7-4744-9654-ABFB59370086Q35537584-F5F2130D-CE1E-480D-9695-4EF6EBBB302CQ35563923-DD5BB278-9256-4ACC-9BCF-2A1E0537B202Q37017344-C16A25BC-C928-4D7B-8E0C-F731B3D29D48Q37128034-A716867C-7C30-48E7-AAA9-AA0F681EEA38Q37615959-3410AA0E-7E87-4B14-AB5D-C1901BED6054Q38051307-A5D2E51A-4D13-452C-B82D-F7E712651DBFQ38069580-76CBFBFC-700D-41F7-9975-B60A1DBBEBD7Q38660895-4A48330E-A791-4DFF-947B-DC14DED23036Q41778993-2FE7DAC7-3FDF-4B3D-8E0E-F7533C4718E9Q43732336-B2994AFA-C1D1-4CC4-B830-BC20FA1EE3E7Q46797788-D55288F0-1E7A-4518-879D-000B7CD2D262Q47966525-478623DC-911B-4F87-AC0B-272A7A12275A
P2860
Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Efficacy of inhaled salmeterol ...... o controlled, crossover study.
@ast
Efficacy of inhaled salmeterol ...... o controlled, crossover study.
@en
type
label
Efficacy of inhaled salmeterol ...... o controlled, crossover study.
@ast
Efficacy of inhaled salmeterol ...... o controlled, crossover study.
@en
prefLabel
Efficacy of inhaled salmeterol ...... o controlled, crossover study.
@ast
Efficacy of inhaled salmeterol ...... o controlled, crossover study.
@en
P2860
P356
P1433
P1476
Efficacy of inhaled salmeterol ...... o controlled, crossover study.
@en
P2093
P2860
P304
P356
10.1136/THX.50.7.750
P407
P577
1995-07-01T00:00:00Z